evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,133 questions · 1,153 findings · 36 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 407 · 35.3%GRADE not reported 90 · 7.8%Very low 183 · 15.9%Low 209 · 18.1%Moderate 211 · 18.3%High 53 · 4.6%

Imiquimod vs surgical excision

Recurrence · adults with basal cell carcinoma of the skin

Imiquimod probably leads to higher recurrence at 3 years compared with surgical excision (moderate certainty).

2 findings from 1 review

Imiquimod vs surgical excision

Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin

Imiquimod showed no clear difference in pain (moderate/severe) compared with surgical excision (low certainty).

1 finding from 1 review

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).

1 finding from 1 review

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA) (20 mg/kg/d for 20 days) vs placebo + IVMA

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).

1 finding from 1 review

Thermotherapy one session (at 50 ºC for 30 seconds) vs meglumine antimoniate (20 mg Sb5/kg/day

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).

1 finding from 1 review

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).

1 finding from 1 review

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day

Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).

1 finding from 1 review